| Description |
Recombinant Mouse ALK Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Ser19-Cys692. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
P97793 |
| Target Symbol |
ALK |
| Synonyms |
ALK tyrosine kinase receptor; Anaplastic lymphoma kinase; CD246; |
| Species |
Mouse |
| Expression System |
HEK293 |
| Tag |
C-hFc |
| Expression Range |
Ser19-Cys692 |
| Mol. Weight |
The protein has a predicted MW of 101.11 kDa. Due to glycosylation, the protein migrates to 115-125 kDa based on Tris-Bis PAGE result. |
| Form |
Liquid |
| Formulation |
Supplied as 0.22um filtered solution in PBS, 10% Glycerol (pH 7.4). |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Storage |
Valid for 12 months from date of receipt when stored at -80°C.; Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Shipping |
Shipped with dry ice. |
| Gene Background |
Anaplastic lymphoma kinase (ALK) is mostly known for its oncogenic role in several human cancers. Recent evidences clearly indicate new roles of ALK and its genetic aberrations (e.g. gene rearrangements and mutations) in immune evasion, innate and cell-mediated immunity. New ALK-related immunotherapy approaches are demonstrating both preclinical and clinical promises. |
